102 related articles for article (PubMed ID: 21128077)
1. KRAS mutation analysis as a diagnostic tool.
Yan B; Chin SY; Ismail TM; Salto-Tellez M
Int J Colorectal Dis; 2011 Aug; 26(8):1083-4. PubMed ID: 21128077
[No Abstract] [Full Text] [Related]
2. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.
Billah S; Stewart J; Staerkel G; Chen S; Gong Y; Guo M
Cancer Cytopathol; 2011 Apr; 119(2):111-7. PubMed ID: 21400670
[TBL] [Abstract][Full Text] [Related]
3. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.
Freidin MB; Freydina DV; Leung M; Montero Fernandez A; Nicholson AG; Lim E
Clin Chem; 2015 Oct; 61(10):1299-304. PubMed ID: 26272233
[TBL] [Abstract][Full Text] [Related]
5. [Is it possible to use molecular biology techniques on endobronchial ultrasound-guided transbronchial needle aspirations (EBUS-PTBA)? A challenge].
Gounant V; Fleury-Feith J; Wislez M
Rev Mal Respir; 2013 May; 30(5):345-7. PubMed ID: 23746810
[No Abstract] [Full Text] [Related]
6. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
7. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
[TBL] [Abstract][Full Text] [Related]
8. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
[TBL] [Abstract][Full Text] [Related]
9. Does a cost-effective approach for the determination of KRAS mutations maximize the patient's benefit in a clinical setting?
Kobunai T; Watanabe T; Yamamoto Y; Fukusato T
Pharmacogenomics; 2011 Mar; 12(3):307-8; author reply 309-10. PubMed ID: 21449668
[No Abstract] [Full Text] [Related]
10. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
Glynn C; Zakowski MF; Ginsberg MS
J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
[TBL] [Abstract][Full Text] [Related]
11. Setting future standards for KRAS testing in colorectal cancer.
van Krieken H; Tol J
Pharmacogenomics; 2009 Jan; 10(1):1-3. PubMed ID: 19102707
[No Abstract] [Full Text] [Related]
12. [Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas].
Qiu T; Ling Y; Chen Z; Shan L; Guo L; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):599-602. PubMed ID: 23157827
[TBL] [Abstract][Full Text] [Related]
13. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
[No Abstract] [Full Text] [Related]
14. Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.
Ayyoub M; Memeo L; Alvarez-Fernández E; Colarossi C; Costanzo R; Aiello E; Martinetti D; Valmori D
Cancer Immunol Res; 2014 Oct; 2(10):943-8. PubMed ID: 24866168
[TBL] [Abstract][Full Text] [Related]
15. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
17. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect.
Munfus-McCray D; Cui M; Zhang Z; Gabrielson E; Askin F; Li QK
Hum Pathol; 2013 Jul; 44(7):1286-92. PubMed ID: 23337026
[TBL] [Abstract][Full Text] [Related]
19. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
[TBL] [Abstract][Full Text] [Related]
20. KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.
Gottschling S; Penzel R; Pelz T; Herpel E; Schnabel PA; Dyckhoff G; Thomas M; Kuhnt T
J Clin Oncol; 2011 Jul; 29(21):e616-9. PubMed ID: 21555681
[No Abstract] [Full Text] [Related]
[Next] [New Search]
